AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
← catalyst calendarNCT07403721 · readout in 709 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
464estimated
Sites
24
Countries
Australia, Belgium, Canada +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-04-08 | actual | When the study began enrolling |
| Primary completion | 2028-07-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-07-28 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-11 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic or Locally Advanced Solid Tumors With Microsatellite Instability-high (MSI-H) or Mismatched Repair Deficiency (dMMR)
Intervention
- Drug: AMG 436
Primary outcomes
what the primary-completion date above is the date OFNumber of Participants with a Dose Limiting Toxicity (DLT)
measured Up to 21 days
Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
measured Up to 5 years
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed